Mostrar el registro sencillo del ítem

dc.contributor.authorBoughanem, H.
dc.contributor.authorCabrera-Mulero, A.
dc.contributor.authorHernandez-Alonso, P.
dc.contributor.authorClemente-Postigo, M.
dc.contributor.authorCasanueva Freijo, Felipe 
dc.contributor.authorTinahones, F. J.
dc.contributor.authorMorcillo, S.
dc.contributor.authorCrujeiras Martínez, Ana Belén
dc.contributor.authorMacias-Gonzalez, M.
dc.date.accessioned2022-04-29T10:25:54Z
dc.date.available2022-04-29T10:25:54Z
dc.date.issued2020
dc.identifier.issn1868-7075
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32517740es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16598
dc.description.abstractBACKGROUNDS: Colorectal cancer (CRC) results from the accumulation of epigenetic and genetic changes in colon cells during neoplasic transformation, which the activation of Wingless (Wnt) signaling pathway is a common mechanism for CRC initiation. The Wnt pathway is mainly regulated by Wnt antagonists, as secreted frizzled-related protein (SFRP) family. Indeed, SFRP2 is proposed as a noninvasive biomarker for CRC diagnosis. Vitamin D also antagonizes Wnt signaling in colon cancers cells. Several studies showed that vitamin D was able to alter DNA methylation, although this mechanism is not yet clear. Therefore, the aim of this study was to find an association between circulating 25-OH vitamin D (30th percentile of vitamin D) and the SFRP2 methylation. METHODS: A total of 67 CRC patients were included in the study. These patients were subdivided into two groups based on their 30th percentile vitamin D (20 patients were below, and 47 participants were above the 30th percentile of vitamin D). We investigated the SFRP2 methylation in peripheral blood mononuclear cells (PBMCs), visceral adipose tissue (VAT), CRC tumor tissue, and adjacent tumor-free area. We also determined the relationship between SFRP2 methylation and methylation of carcinogenic and adipogenic genes. Finally, we tested the effect of vitamin D on the SFRP2 methylation in human colorectal carcinoma cell lines 116 (HCT116) and studied the association of neoadjuvant therapy under the 30th percentile vitamin D with SFRP2 promoter methylation. RESULTS: SFRP2 methylation in tumor area was decreased in patients who had higher levels of vitamin D. SFRP2 promoter methylation was positively correlated in tumor area with insulin and homeostasis model assessment of insulin resistance (HOMA-IR) but negatively correlated with HDL-c. SFRP2 methylation was also correlated with T cell lymphoma invasion and metastasis 1 (TIAM1) methylation in tumor area and CCAAT/enhancer-binding protein alpha (C/EBPalpha) in VAT. Treatment with vitamin D did not affect SFRP2 methylation in HCT116 cell line. Finally, neoadjuvant treatment was correlated with higher circulating 25-OH vitamin D and SFRP2 methylation under linear regression model. CONCLUSION: Our results showed that higher circulating vitamin D is associated with low SFRP2 promoter methylation. Therefore, our results could suggest that vitamin D may have an epigenetic effect on DNA methylation. Finally, higher vitamin D could contribute to an improvement response to neoadjuvant treatment.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshMembrane Proteins*
dc.subject.meshNeoadjuvant Therapy*
dc.subject.meshMiddle Aged*
dc.subject.meshEpigenomics*
dc.subject.meshIntra-Abdominal Fat*
dc.subject.meshLinear Models*
dc.subject.meshLeukocytes*
dc.subject.meshHCT116 Cells*
dc.subject.meshWnt Signaling Pathway*
dc.subject.meshHumans*
dc.subject.meshDNA Methylation*
dc.subject.meshVitamin D*
dc.subject.meshAged*
dc.subject.meshColorectal Neoplasms*
dc.titleAssociation between variation of circulating 25-OH vitamin D and methylation of secreted frizzled-related protein 2 in colorectal canceren
dc.typeJournal Articlees
dc.authorsophosBoughanem, H.;Cabrera-Mulero, A.;Hernandez-Alonso, P.;Clemente-Postigo, M.;Casanueva, F. F.;Tinahones, F. J.;Morcillo, S.;Crujeiras, A. B.;Macias-Gonzalez, M.
dc.identifier.doi10.1186/s13148-020-00875-9
dc.identifier.pmid32517740
dc.identifier.sophos39537
dc.issue.number1es
dc.journal.titleCLINICAL EPIGENETICSes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Endocrinoloxíaes
dc.rights.accessRightsopenAccess
dc.subject.decsmodelos lineales*
dc.subject.decsmediana edad*
dc.subject.decstratamiento neoadyuvante*
dc.subject.decsgrasa intraabdominal*
dc.subject.decsmetilación del ADN*
dc.subject.decscélulas HCT116*
dc.subject.decsepigenómica*
dc.subject.decsanciano*
dc.subject.decsproteínas de membranas*
dc.subject.decshumanos*
dc.subject.decsleucocitos*
dc.subject.decsvitamina D*
dc.subject.decsneoplasias colorrectales*
dc.subject.decsvía de señalización Wnt*
dc.subject.keywordIDISes
dc.subject.keywordHULAes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number12es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional